Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity

Journal of Virology

Volumn 80, Issue 14, 2006, Pages 6906-6916

  Foulkes, Jennifer E ^a   Prabu Jeyabalan, Moses ^a   Cooper, Deyna ^a   Henderson, Gavin J ^b,c   Harris, Janera ^b   Swanstrom, Ronald ^b   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ASPARAGINE; PROTEINASE; PROTEINASE INHIBITOR; SAQUINAVIR; SERINE; THREONINE; VALINE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CALCULATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATHEMATICAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTIVITY;

AMINO ACID SUBSTITUTION; ASPARTIC ENDOPEPTIDASES; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; MODELS, MOLECULAR; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TRYPTOPHAN;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 33745830892     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.01900-05     Document Type: Article

References (65)

1. Ala, P. J., E. E. Huston, R. M. Klabe, P. K. Jadhav, P. Y. Lam, and C. H. Chang. 1998. Counteracting HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with XV638 and SD146, cyclic urea amides with broad specificities. Biochemistry 37:15042-1504 9.
2. Ariyoshi, K., M. Matsuda, H. Miura, S. Tateishi, K. Yamada, and W. Sugiura. 2003. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune Defic. Syndr. 33:336-342.
3. Baldwin, E. T., T. N. Bhat, B. Liu, N. Pattabiraman, and J. W. Erickson. 1995. Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat. Struct. Biol. 2:244-249.
4. Beasley, J. R., D. F. Doyle, L. Chen, C. D. S., B. R. Fine, and G. J. Peilak. 2002. Searching for quantitative entropy-enthalpy compensation among protein variants. Proteins Struct. Funct. Genet. 49:398-402.
5. Blasie, C. A., and J. M. Berg. 2004. Entropy-enthalpy compensation in ionic interactions probed in a zinc finger peptide. Biochemistry 43:10600-10604.
6. Case, D. A., T. A. Darden, T. E. Cheatham III, C. L. Simmerling, J. Wang, R. E. Duke, R. Luo, K. M. Mertz, B. Wang, D. A. Pearlman, M. Crowley, S. Brozell, V. Tsui, H. Gohlke, J. Mongan, V. Hornak, G. Cui, P. Beroza, C. Schafmeister, J. W. Caldwell, W. S. Ross, and P. A. Kollman. 2004. AMBER 8. University of California-San Francisco, San Francisco, Calif.
7. L promoter vectors for direct cloning and high level expression of PCR amplified DNA coding sequences. Nucleic Acids Res. 20:4591-4598.
8. Chou, K.-C., A. G. Tomasselli, I. M. Reardon, and R. L. Heinrikson. 1996. Predicting human immunodeficiency virus protease cleavage sites in proteins by a discriminant function method. Proteins 24:51-72.
9. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 257:483-489.
10. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect. D Biol. Crystallogr. 50:760-763.
11. Copeland, R. A. 1996. Enzymes: A practical introduction to structure, mechanism, and data analysis. Wiley-VCH, Weinheim, Germany.
12. Cote, H. C. F., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
13. Dunitz, J. D. 1995. Win some, lose some: enthalpy-entropy compensation in weak intermolecular interactions. Chem. Biol. 2:709-712.
14. Erickson, J. W., and S. K. Burt. 1996. Structural mechanisms of HIV drug resistance. Annu. Rev. Pharmacol. Toxicol. 36:545-571.
15. Ermolieff, J., X. Lin, and J. Tang. 1997. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo. Biochemistry 36:12364-12370.
16. Ferrin, T. E., C. C. Huang, L. E. Jarvis, and R. Langridge. 1988. The MIDAS display system. J. Mol. Graph. 6:13-27.
17. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
18. Henderson, L. E., T. D. Copeland, R. C. Sowder, A. M. Schultz, and S. Oraszlan. 1988. Human retroviruses, cancer and AIDS: approaches to prevention and therapy. Liss, New York, N.Y.
19. Hong, L., X. C. Zhang, J. A. Hartsuck, and J. Tang. 2000. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 9:1898-1904.
20. Hui, J. O., A. G. Tomasselli, I. M. Reardon, J. M. Lull, D. P. Brunner, C.-S. C. Tomich, and R. L. Heinrikson. 1993. Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies. J. Protein Chem. 12:323-327.
21. Ji, J. P., and L. A. Loeb. 1992. Fidelity of HIV-1 reverse transcriptase copying RNA in vitro. Biochemistry 31:954-958.
22. Jones, T. A., M. Bergdoll, and M. Kjeldgaard. 1990. O: a macromolecular modeling environment, p. 189-195. In C. Bugg and S. Ealick (ed.), Crystallographic and modeling methods in molecular design. Springer-Verlag, Berlin, Germany.
23. Kantor, R., and D. Katzenstein. 2004. Drug resistance in non-subtype B HIV-1. J. Clin. Virol. 29:152-159.
24. Kantor, R., R. W. Shafer, S. Follansbee, J. Taylor, D. Shilane, L. Hurley, D. P. Nguyen, D. Katzenstein, and W. J. Fessel. 2004. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18:1503-1511.
25. King, N. M., L. Melnick, M. Prabu-Jeyabalan, E. A. Nalivaika, S.-S. Yang, Y. Gao, X. Nie, C. Zepp, D. L. Heefner, and C. A. Schiffer. 2002. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 11:418-429.
26. King, N. M., M. Prabu-Jeyabalan, P. Wigerinck, M.-P. De Bethune, and C. A. Schiffer. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78:12012-12021.
27. Klabe, R. M., L. T. Bacheler, P. J. Ala, S. Erickson-Viitanen, and J. L. Meek. 1998. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 37:8735-8742.
28. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
29. Krohn, A., S. Redshaw, J. C. Ritchie, B. J. Graves, and M. H. Hatada. 1991. Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere. J. Med. Chem. 34:3340-3342.
30. Kuriyan, J., and W. I. Weis. 1991. Rigid protein motion as a model for crystallographic temperature factors. Proc. Natl. Acad. Sci. USA 88:2773-2777.
31. Laskowski, R. A., M. W. Mac Arthur, D. S. Moss, and J. M. Thornton. 1993. PROCHECK. A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283-291.
32. Maguire, M. F., R. Guinea, P. Griffin, S. MacManus, R. C. Elston, J. Wolfram, N. Richards, M. H. Hanlon, D. J. T. Porter, T. Wrin, N. Parkin, M. Tisdale, E. S. Furfine, C. Petropoulos, B. W. Snowden, and J. P. Kleim. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76: 7398-7406.
33. Maschera, B., G. Darby, G. Palu, L. L. Wright, M. Tisdale, R. Myers, E. D. Blair, and E. S. Furfine. 1996. Human immunodeficiency virus: mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271: 33231-33235.
34. Matayoshi, E., G. Wang, G. Krafft, and J. Erickson. 1990. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247:954-958.
35. Minor, W. 1993. XDISPLAYF program. Purdue University, West Lafayette, Ind.
36. Morris, R. J., A. Perrakis, and V. S. Lamzin. 2002. ARP/wARP's model-building algorithms. I. The main chain. Acta Crystallogr. Sect. D Biol. Crystallogr. 58:968-975.
37. Munshi, S., Z. Chen, Y. Yan, Y. Li, D. Olsen, H. Schock, B. Galvin, B. Dorsey, and L. Kuo. 2000. An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease. Acta Crystallogr. Sect. D Biol. Crystallogr. 56(Pt. 4):381-388.
38. Murshudov, G. N., A. A. Vagin, and E. J. Dodson. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. Sect. D Biol. Crystallogr. 53:240-255.
39. Muzammil, S., P. Ross, and E. Freire. 2003. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42:631-638.
40. Navaza, J. 1994. AMoRe: an automated package for molecular replacement. Acta Crystallogr. Sect. A 50:157-163.
41. Ohtaka, H., A. Schon, and E. Freire. 2003. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations. Biochemistry 42:13659-13666.
42. Ohtaka, H., A. Velazquez-Campoy, D. Xie, and E. Freire. 2002. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11:1908-1916.
43. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
44. Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76:10226-10233.
45. Pettit, S. C., N. Sheng, R. Tritch, S. Erickson-Vitanen, and R. Swanstrom. 1998. The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv. Exp. Med. Biol. 436:15-25.
46. Prabu-Jeyabalan, M., E. Nalivaika, N. M. King, and C. A. Schiffer. 2004. Structural basis for coevolution of the human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78:12446-12454.
47. Prabu-Jeyabalan, M., E. Nalivaika, and C. A. Schiffer. 2000. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. J. Mol. Biol. 301:1207-1220.
48. Prabu-Jeyabalan, M., E. A. Nalivaika, N. M. King, and C. A. Schiffer. 2003. Viability of a drug-resistant HIV-1 protease variant: structural insights for better antiviral therapy. J. Virol. 77:1306-1315.
49. Resch, W., R. Ziermann, N. Parkin, A. Gamarnik, and R. Swanstrom. 2002. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 76:8659-8666.
50. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
51. Roberts, J. D., B. D. Preston, L. A. Johnston, et al. 1989. Fidelity of two retroviral reverse transcriptases during DNA-dependent DNA synthesis in vitro. Mol. Cell. Biol. 9:469-476.
52. Roberts, N. A. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9(Suppl. 2):S27-S32.
53. Robins, T., and J. Plattner. 1993. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J. Acquir. Immune Defic. Syndr. 6:162-170.
54. Rose, J. R., R. Salto, and C. S. Craik. 1993. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J. Biol. Chem. 268:11939-11945.
55. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 5:129-142.
56. Schomaker, V., and K. N. Trueblood. 1968. On the rigid body motion of molecules in crystals. Acta Crystallogr. Sect. B 24:63-76.
57. Scott, W. R. P., and C. A. Schiffer. 2000. Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance. Structure 8:1259-1265.
58. Shafer, R. W., D. Stevenson, and B. Chan. 1999. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 27:348-352.
59. Sharp, K. 2001. Enthalpy-entropy compensation: fact or artifact? Protein Sci. 10:661-667.
60. Sigurskjold, B. 2000. Exact analysis of competition ligand binding by displacement isothermal titration calorimetry. Anal. Biochem. 277:260-266.
61. Tickle, I. J., and D. S. Moss. 1999. Modelling rigid-body thermal motion in macromolecular crystal structure refinement. IUCr99 Computing School, London, United Kingdom. [Online.] http://people.cryst.bbk.ac.uk/∼tickle /iucr99/.
62. Todd, M. J., I. Luque, A. Velazquez-Campoy, and E. Freire. 2000. Thermodynamic basis of resistance to HIV-1 protease inhibition: calorimetric analysis of the V82F/I84V active site resistant mutant. Biochemistry 39:11876-11883.
63. Tözsér, J., I. Blaha, T. D. Copeland, E. M. Wondrak, and S. Oroszlan. 1991. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrate representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281:77-80.
64. Velazquez-Campoy, A., Y. Kiso, and E. Freire. 2001. The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch. Biochem. Biophys. 390:169-175.
65. Xie, D., S. Gulnik, E. Gustchina, B. Yu, W. Shao, W. Qoronfleh, A. Nathan, and J. W. Erickson. 1999. Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8:1702-1707.